A Prospective Efonidipine Efficacy Evaluation in Cardiovascular and Renal Outcomes in Hypertensive Patients: The PERFECT Trial
DOI:
https://doi.org/10.14738/bjhmr.115.17583Keywords:
Efonidipine, Hypertension, Cardioprotection, Renoprotection, Calcium Channel BlockerAbstract
Background: Efonidipine, an L and T-type calcium channel blocker (CCB), is known for effectively lowering blood pressure and targeting proteinuria by balancing glomerular capillary pressure. There remains a gap in understanding how its clinical benefits and safety profile compare to other CCBs, particularly those targeting L and N-type channels. The present trial evaluated the effect of Efonidipine and Cilnidipine on cardiovascular and renal outcomes in hypertensive patients. Methods: A randomized, comparative trial was conducted from May 2019 to August 2023 in adults with hypertension (≥140/90 mmHg). The patients (n=1035) received one of the drugs daily for 90 days. The primary endpoint was the change in blood pressure with secondary endpoints including improvement in proteinuria, and safety assessment. Results: Both Efonidipine and Cilnidipine reduced blood pressure to a similar extent (Efonidipine, from 155.17 ± 10.38 to 132.92 ± 9.60 mmHg, p<0.001; Cilnidipine, from 154.75 ± 10.05 to 132.90 ± 9.47 mmHg, p<0.001) and maintained heart rate significantly lower from baseline (Efonidipine, from 83.5 ± 7.2 to 80.1 ± 6.3 beats/ min, p<0.001; Cilnidipine, from 83.3 ± 6.9 to 80.0 ± 6.8 beats/min; p<0.001). Efonidipine demonstrated a more pronounced reduction (from 151.45 ± 4.4 to 123.52 ± 3.9 mg/g Cr, p<0.001) in proteinuria compared to Cilnidipine (from 161.64 ± 8.9 to 152.10 ± 3.9 7.8 mg/g Cr, p=4240). An independent decrease in proteinuria relative to blood pressure reduction was observed with Efonidipine. Adverse events were similar between groups, with no incidences of peripheral edema. Conclusion: Efonidipine and Cilnidipine effectively controlled blood pressure and reduced proteinuria. The antiproteinuric effect was more apparent with Efonidipine. Efonidipine improves cardiovascular and renal outcomes and may be considered an initial treatment option in hypertensive patients.
References
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003
Currie G, Delles C. Prosteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis. 2014; 7:13-24 doi:10.2147/IJNRD.S40522
Lee H, Park MS, Kang MK, Song TJ. Association between Proteinuria Status and Risk of Hypertension: A Nationwide Population-Based Cohort Study. J Pers Med. 2023;13(9):1414. doi: 10.3390/jpm13091414
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480
Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066
Shetty S, Malik AH, Feringa H, El Accaoui R, Girotra S. Meta-Analysis Evaluating Calcium Channel Blockers and the Risk of Peripheral Arterial Disease in Patients with Hypertension. Am J Cardiol. 2020;125(6):907-915. doi: 10.1016/j.amjcard.2019.12.026
Ghamami N, Chiang SH, Dormuth C, Wright JM. Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst Rev. 2014;(8):CD010052.
Lee EM. Calcium channel blockers for hypertension: old, but still useful. Cardiovasc Prev Pharmacother. 2023;5(4):113-125. doi:10.36011/cpp.2023.5. e16
Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14(1):67-72. doi: 10.11909/j.issn.1671-5411.2017.01.006
Abe M, Soma M. Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection. Hypertens Res. 2015;38(12):804-806. doi:10.1038/hr.2015.106
Tanaka H, Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type Ca2+ channels. Cardiovasc Drug Rev. 2002;20(1):81-92
Masuda Y, Miyajima M, Shudo C, Tanaka S, Shigenobu K, Kasuya Y. Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues. Gen Pharmacol. 1995;26(2):339-345. doi:10.1016/0306-3623(94)00187-r
Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res. 1996;19(1):31-36. doi:10.1291/hypres.19.31
Honda M, Hayashi K, Matsuda H, et al. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens. 2001;19(11):2031-2037. doi:10.1097/00004872-200111000-00014
Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens. 2003;16(2):116-122. doi:10.1016/s0895-7061(02)03147-3
Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res. 2007;30(7):621-626.
Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res. 2007;30(8):691-697. doi:10.1291/hypres.30.691
Nakano N, Ishimitsu T, Takahashi T, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010;51(3):188-192. doi:10.1536/ihj.51.188
Sasaki H, Saiki A, Endo K, et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb. 2009; 16(5): 568-75
Oshima, T., Ozono, R., Yano, Y. et al. Beneficial Effect of T-Type Calcium Channel Blockers on Endothelial Function in Patients with Essential Hypertension. Hypertens Res. 2005;28(11): 889–894. doi:10.1291/hypres.28.889
Chandra KS, Ramesh G. The fourth-generation Calcium channel blocker: cilnidipine. Indian Heart J. 2013;65(6):691-695. doi: 10.1016/j.ihj.2013.11.001
Chakraborty RN, Langade D, More S, Revandkar V, Birla A. Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials. Cureus. 2021;13(11): e19822. doi:10.7759/cureus.19822
National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9630/
Lee H, Kwon SH, Jeon JS, Noh H, Han DC, Kim H. Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients. Kidney Res Clin Pract. 2022;41(1):31-42. doi: 10.23876/j.krcp.21.099
Wu S, Li M, Lu J, et al. Blood Pressure Levels, Cardiovascular Events, and Renal Outcomes in Chronic Kidney Disease Without Antihypertensive Therapy: A Nationwide Population-Based Cohort Study. Hypertension. 2023;80(3):640-649. doi:10.1161/HYPERTENSIONAHA.122.19902
Dewan B, Wani V. A Comparative Clinical Trial of Efonidipine and Amlodipine in Management of Stage-I Hypertension: A Randomized, Double-Blind Study in Indian Population. JAMMR. 2018;25(1):1-12. doi: 10.9734/JAMMR/2018/38509
Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney international. 2007;72(12):1543-9
Tanaka H, Masumiya H, Sekine T, et al. Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem. Gen Pharmacol. 1996;27(3):451-4. doi: 10.1016/0306-3623(95)02065-9
Takeda K, Yamagishi R, Masumiya H, Tanaka H, Shigenobu K. Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node. J Pharmacol Sci. 2004;95(3):398-401. doi: 10.1254/jphs. scj04001x
Shete MM. Cilnidipine: Next Generation Calcium Channel Blocker. J Assoc Physicians India. 2016 Apr;64(4):95-99. PMID: 27734656.
Li X, Yang MS. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis. PLoS One. 2014;9(10): e109834. doi: 10.1371/journal.pone.0109834
Srivathsan M, Vardhan V, Naseem A, Patil S, Rai V, Langade DG. Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers: A Meta-Analysis of Randomized Controlled and Retrospective Studies. Cureus. 2022;14(8): e27847. doi: 10.7759/cureus.27847
Thamcharoen N, Susantitaphong P, Wongrakpanich S, et al. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res. 2015 Dec;38(12):847-55. doi: 10.1038/hr.2015.69
Hayashi K, Homma K, Wakino S, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med. 2010;59(3):84-95. doi:10.2302/kjm.59.84
Suzuki Y, Kaneko H, Okada A, et al. Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Am J Cardiol. 2022 Apr 1; 168:83-89. doi: 10.1016/j.amjcard.2021.12.023.
Hayashi K, Saruta T, Goto Y, Ishii M; JATOS Study Group. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res. 2010;33(11):1211-20. doi: 10.1038/hr.2010.162
Imagawa K, Okayama S, Takaoka M, et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol. 2006;47(1):133-8. doi: 10.1097/01.fjc.0000197539. 12685.f5
Okayama S, Imagawa K, Naya N, et al. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res. 2006;29(7):493-7. doi: 10.1291/hypres.29.493
Fujiwara K, Kanno Y, Hayashi K, Takenaka T, Saruta T. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens. 1998;20(3):295-312. doi:10.3109/10641969809052123
Sugano N, Wakino S, Kanda T, et al. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 2008;73(7):826-34. doi: 10.1038/sj.ki.5002793.
Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol. 1998;349(2-3):351-357. doi:10.1016/s0014-2999(98)00204-0
Jariwala P, Jadhav K, The safety and efficacy of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in Indian patients with mild-to-moderate essential hypertension, European Heart Journal, 2022;43: Supplement_1: ehab849.143. doi: 10.1093/eurheartj/ehab849.143
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Bhupesh Dewan, Siddheshwar Shinde, Shweta Kondekar, Nisha Motwani
This work is licensed under a Creative Commons Attribution 4.0 International License.
